Beaver Run Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2019



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Phenotypic Drug Discovery: Recent Advances and Insights from Chemical and Systems Biology (C1)


Organizer(s) Mark Mercola, Fabien Vincent, Monica Schenone and Arsenio Nueda
March 3—7, 2019
Beaver Run Resort • Breckenridge, Colorado USA
Discounted Abstract Deadline: Oct 30, 2018
Abstract Deadline: Dec 4, 2018
Scholarship Deadline: Oct 30, 2018
Discounted Registration Deadline: Jan 11, 2019

Sponsored by Merck & Co., Inc. and Pfizer Inc.

Summary of Meeting:
Unlike conventional target-centric drug discovery, Phenotypic Drug Discovery (PDD) places its focus on disease-relevant phenotypes and agnosticism with regard to molecular mechanism of action. Thus, it offers unique opportunities in terms of discovery of novel biology and first-in-class therapeutics but is matched with significant challenges, a number of which can be addressed by recent advances in chemical and systems biology. A key aspect of the conference will be to share information and processes on how best to employ phenotypic strategies to discover novel biology and effectively prosecute drug discovery programs. Specific topics will include: chemical biology advances and case studies in target identification; case studies of recently advanced clinical candidates and approved drugs; functional genomics and systems biology advances and case studies; project prosecution including lessons learned from lead optimization and pre-clinical development; complex cell-based models and new assay modalities. With few non-commercial meetings covering drug discovery as a discipline, this conference has the stature and breadth to bring together accomplished and influential scientists from industry and academia as demonstrated by the 2016 conference. Its scope will be broader than other PDD and Chemical Biology meetings since it will cover the entire range of activities and technologies from phenotypic assay systems, to target identification and FDA approval of novel therapeutics. Given that there is still an emphasis on target centric discovery in pharmaceutical companies, this conference can be instrumental in further promoting a shift in mindset and contributing to the consolidation of PDD as an integral part of the drug discovery paradigm. The vision for this conference would be to share success stories of newly approved drugs and late stage clinical candidates, along with key lessons and best practices, to inform future PDD projects.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Sunday, March 3 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 7 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 8 in order to fully experience the meeting.

SUNDAY, MARCH 3

16:00—20:00
Arrival and Registration

Colorado Ballroom Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Colorado Ballroom Foyer

MONDAY, MARCH 4

07:00—08:00
Breakfast

Summit Gallery
08:00—09:15
Welcoming Remarks and Keynote Address
Meeting has ended...abstracts no longer viewable online.
Big picture view of pharmaceutical development, challenges and new opportunities.

Colorado Ballroom
* Mark Mercola, Stanford University, USA

James E. Bradner, Novartis Institutes for BioMedical Research, USA
Phenotype to Chemotype to Phenotype

09:15—11:15
Clinical Success Stories
Meeting has ended...abstracts no longer viewable online.
Share success stories – newly approved drugs and late stage clinical candidates. Identify key lessons and best practices to inform future PDD projects.

Colorado Ballroom
* Tom Large, Blue Oak Pharmaceuticals, USA

Yoshihiro Watanabe, Kanazawa University, Japan
Discovery of Trametinib as a MEK-Inhibitor Able to Alter Phosphorylation State of MEK

Coffee Break

Fred Van Goor, Vertex Pharmaceuticals Incorporated, USA
Combination Pharmacology to Treat the Underlying Cause of the Majority of People with Cystic Fibrosis

John Tallarico, Novartis Institutes for BioMedical Research, USA
Novel Therapies from Phenotypic Screening

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Breckenridge Ballroom
13:00—22:00
Poster Viewing

Breckenridge Ballroom
14:30—15:30
Workshop: Safety De-Risking

Colorado Ballroom
Gerhard Ecker, University of Vienna, Austria
Semantically Integrated Life Science Data – The Power of Workflows for Analysis of Phenotypic Screening Data, Toxicological Read-Across, and Repurposing

Ellen L. Berg, Eurofins DiscoverX, USA
Phenotypic Profiling for Toxicity-Associated Signatures Applied to ToxCast Chemicals

* Fabien Vincent, Pfizer Inc., USA
Safety De-Risking in Phenotypic Drug Discovery: Considerations and Strategies

15:30—16:30
Panel Discussion

Colorado Ballroom
Ellen L. Berg, Eurofins DiscoverX, USA

Neil O. Carragher, University of Edinburgh, Scotland

Chun-wa Chung, GlaxoSmithKline, UK

Tom Large, Blue Oak Pharmaceuticals, USA

16:30—17:00
Coffee Available

Colorado Ballroom Foyer
17:00—19:00
New Opportunities and Under-Represented Indications
Meeting has ended...abstracts no longer viewable online.
Illustrate new opportunities for PDD among hard to study and treat diseases. Illustrate new disease modeling technology that can be a breakthrough in finding drug targets and drugs.

Colorado Ballroom
* Jonathan A. Lee, PDD4Patients LLC, USA

Lucienne V. Ronco, Fulcrum Therapeutics, USA
Identification of FTX-1821 a Molecule that Inhibits DUX4 Expression and Rescues FSHD Pathophysiology in FSHD Skeletal Muscle Myotubes

Clemens R. Scherzer, Harvard Medical School, Brigham and Women's Hospital, USA
Turning Bits and Base Pairs into Precision Neurology

Scott S. Walker, Merck & Co., Inc., USA
Large-Scale Antibacterial Phenotypic Screening and Systematic Hit Triage Reveal Novel Targets and Novel Inhibitors of Established Targets

Eachan Oliver Johnson, Broad Institute, USA
Short Talk: Large-Scale Chemical-Genetic Interaction Profiling Yields New Classes of Inhibitors of Mycobacterium tuberculosis

Patrick W. Faloon, Biogen, USA
Short Talk: Identification of Small Molecules that Increase Productive Cellular Processing of Antisense Oligonucleotides (ASOs)

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom
19:30—22:00
Poster Session 1

Breckenridge Ballroom

TUESDAY, MARCH 5

07:00—08:00
Breakfast

Summit Gallery
08:00—11:15
Chemical Biology and Novel Molecular Mechanisms of Action
Meeting has ended...abstracts no longer viewable online.
Drugging targets considered traditionally undruggable. Small molecule probing of protein conformation/function.

Colorado Ballroom
* Susanne Swalley, Biogen, USA

Maurizio Pellecchia, University of California, Riverside, USA
NMR-Based Fragment Screening for Oncology

Laura L. Kiessling, Massachusetts Institute of Technology, USA
Glycans in Health and Disease

Coffee Break

Razvan L. Cornea, University of Minnesota, USA
Targeting the Pathological Leak of a Calcium Channel for Heart Failure Therapeutics

Monica Schenone, Pfizer Inc., USA
Identification of p300/CBP as the Cellular Target of the Small Molecule “BRD16” Following a Phenotypic Screen

Sannah Zoffmann, F. Hoffmann-La Roche Ltd., Switzerland
Short Talk: Machine Learning-Powered Antibiotics Phenotypic Drug Discovery

Jean-Philippe Coppe, University of California, San Francisco, USA
Short Talk: Mapping Phospho-Catalytic Dependencies of Therapy-Resistant Tumors Reveals New Actionable Vulnerabilities

Julien Olivet, Dana-Farber Cancer Institute, USA
Short Talk: Systematic Assessment of Druggable Cavities in a Histone Deacetylase Complex

11:15—12:15
Panel Discussion: Comparing/Contrasting the Practice of PDD
The discussion seeks to examine how PDD is viewed and practiced within various types of organizations (such as academia, industry, government, and start-ups). Rather than focusing on specific scientific projects, the discussion will seek to compare/contrast opinions, attitudes and experiences related to PDD from diverse environments. Discussion points will include, but are not limited to: perceived acceptance/importance of PDD, when/why PDD (vs TDD) is used, perceived strengths/weaknesses of PDD, experiences related to obtaining “buy-in” from managers/VC/funding agencies, therapeutic fit, what works in your organization, what needs to be improved.

Colorado Ballroom
* Jonathan A. Lee, PDD4Patients LLC, USA

Neil O. Carragher, University of Edinburgh, Scotland

Bruce Posner, University of Texas Southwestern Medical Center, USA

Veronica Soloveva, Merck, USA

Bridget Wagner, Broad Institute, USA

Guillermo Vela, NeuScience, USA

Arsenio Nueda, Almirall S.A., Spain

Christophe Antczak, Novartis Institutes for BioMedical Research, USA

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Breckenridge Ballroom
13:00—22:00
Poster Viewing

Breckenridge Ballroom
16:30—17:00
Coffee Available

Colorado Ballroom Foyer
17:00—19:00
Project Prosecution and Pre-Clinical Advancement
Meeting has ended...abstracts no longer viewable online.
Addressing roadblocks in advancing drugs from phenotypic assays through pre-clinical development. Strategies for selecting high probability leads.

Colorado Ballroom
* Scott Wolkenberg, Merck and Co., Inc., USA

Arsenio Nueda, Almirall S.A., Spain
Harnessing the Power of Phenotypic Screening to Generate Novel Starting Points for Drug Discovery

Chun-wa Chung, GlaxoSmithKline, UK
Linking Differential Molecular Mode of Action to Distinct Pharmacology

Derek Lowe, Novartis Institutes for BioMedical Research, USA
Advancement of Phenotypic Hits

Hassan Javanbakht, Gilead Sciences, USA
Short Talk: Phenotypic Screening in Antiviral Research

Hassan Al-Ali, University of Miami, USA
Short Talk: Re-Thinking Drug Target Identification and Exploiting Polypharmacology

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom
19:30—22:00
Poster Session 2

Breckenridge Ballroom

WEDNESDAY, MARCH 6

07:00—08:00
Breakfast

Summit Gallery
08:00—11:00
Physiologically Complex and Realistic Disease Assays
Meeting has ended...abstracts no longer viewable online.
Incorporating advances in stem cell disease modeling into drug discovery. Technological advances in complex and kinetic readouts. 3D organoids.

Colorado Ballroom
* Tao Zhong, School of Life Sciences, East China Normal University, China

Randall T. Peterson, University of Utah, USA
Zebrafish Behaviors as Phenotypes for Neuroactive Compound Discovery

Mark Mercola, Stanford University, USA
High-Throughput Kinetic Studies of iPSC-Derived Cardiomyocytes: Bringing the Patient to the Early Stages of Drug Discovery

Coffee Break

Neil O. Carragher, University of Edinburgh, Scotland
Advances in Phenotypic Screening: Accelerating the Discovery of New Chemical Entities and Drug Combinations towards in vivo Proof-of-Concept

Christy Fryer, Novartis Institutes for Biomedical Research, USA
Discovery of a ZIP7 Inhibitor from a Notch Pathway Screen

Kristin Rockwell, Pfizer, USA
Short Talk: Functional Genomics Screening in Primary Human T Cells to Identify Novel Targets for Autoimmune Diseases

11:00—17:00
On Own for Lunch

14:30—15:30
Workshop: Clinical, Regulatory Case Studies with PDD Project Prosecution

Colorado Ballroom
* Marco Prunotto, F. Hoffmann-La Roche Ltd., Switzerland

Yevgeny Berdichevsky, Lehigh University, USA
Screen in Organotypic Hippocampal Model of Drug-Resistant Epilepsy Reveals Novel Anticonvulsants

Herve Tiriac, University of California, San Diego, USA
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

Kerry L. Spear, Blue Oak Pharmaceuticals, USA
Next Generation of Drugs for Bipolar Depression: A Systems Biology Approach

15:30—16:30
Panel Discussion
Panelists to be determined.

Colorado Ballroom
16:30—17:00
Coffee Available

Colorado Ballroom Foyer
17:00—19:00
Functional Genomics and Systems Approaches
Meeting has ended...abstracts no longer viewable online.
Functional genomics, machine learning and data mining.

Colorado Ballroom
* Aravind Subramanian, Broad Institute, USA

Anna Greka, Harvard Medical School, USA
Toward Targeted, Mechanism-Based Therapies for Kidney Diseases

Alexandre R. Colas, Sanford-Burnham Medical Research Institute, USA
Novel Single Cell and High-Throughput Phenotypical Platform to Study Atrial Rhythm in hPSCs

Francisca Vazquez, Broad Institute of Harvard and MIT, USA
Defining a Cancer Dependency Map

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom

THURSDAY, MARCH 7

07:00—08:00
Breakfast

Summit Gallery
08:00—09:00
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Monica Schenone, Pfizer Inc., USA

Benjamin F. Cravatt III, The Scripps Research Institute, USA
Activity-Based Proteomics – Protein and Ligand Discovery on a Global Scale

09:00—11:30
Compound Profiling and Repositioning
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* John Moffat, Genentech, Inc., USA

Christopher A. Lipinski, Chrstopher A. Lipinski PhD LLC, USA
High-Throughput in vivo Phenotypic Screening for Drug Repurposing: Discovery of MLR-1023, a Novel Insulin Sensitizer and Novel Lyn Kinase Activator with Clinical Proof-of-Concept

Coffee Break

Marco Prunotto, F. Hoffmann-La Roche Ltd., Switzerland
Molecular Information Phenotype-Based Drug Discovery: A 5 Year Journey

Bruce Posner, University of Texas Southwestern Medical Center, USA
Identifying Subtype-Selective Vulnerabilities and Biomarkers in Non-Small Cell Lung Cancer

Mo Mandegar, Tenaya Therapeutics, USA
Short Talk: Artificial Intelligence Accelerates Early-Stage Target and Drug Discovery

Christian T. Meyer, Vanderbilt University, USA
Short Talk: A Consensus Framework for Calculating Drug Synergy

11:30—17:00
On Own for Lunch

16:30—17:00
Coffee Available

Colorado Ballroom Foyer
17:00—18:45
Target Identification / Deconvolution
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
* Ellen L. Berg, Eurofins DiscoverX, USA

Dyann F. Wirth, Harvard School of Public Health, USA
Target ID for Malaria

Bridget Wagner, Broad Institute, USA
The Importance of Phenotypic Screening in Identifying New Targets for Disease Therapeutics

Herbert Waldmann, Max Planck Institute for Molecular Physiology, Germany
Chemotype – Phenotype - Target

Heidi Greulich, Broad Institute of MIT and Harvard, USA
Short Talk: PDE3A Modulation for the Treatment of Cancer

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.

Colorado Ballroom
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Peaks 1-3
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Peaks 1-3

FRIDAY, MARCH 8

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Merck & Co., Inc. Pfizer Inc.

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health
National Center for Advancing Translational Sciences (NCATS)

Grant No. 1R13TR002707-01

Funding for this conference was made possible (in part) by 1R13TR002707-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional support for this conference from:

Agilent

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Almirall, S.A.


Eurofins DiscoverX


Merck & Co., Inc.


Pfizer Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org,
Phone:+1 970-262-1179